Balaji Prasad
Stock Analyst at Barclays
(2.34)
# 2,527
Out of 4,681 analysts
137
Total ratings
42.48%
Success rate
-0.94%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PAHC Phibro Animal Health | Maintains: Underweight | $13 → $20 | $23.54 | -15.04% | 7 | Nov 12, 2024 | |
| PCRX Pacira BioSciences | Maintains: Equal-Weight | $25 → $17 | $17.81 | -4.55% | 7 | Nov 12, 2024 | |
| VTRS Viatris | Maintains: Underweight | $11 → $12 | $13.20 | -9.09% | 7 | Nov 8, 2024 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $19 → $20 | $13.48 | +48.37% | 12 | Nov 8, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Overweight | $125 → $150 | $122.70 | +22.25% | 14 | Nov 8, 2024 | |
| RDY Dr. Reddy's Laboratories | Maintains: Overweight | $17 → $17 | $14.30 | +18.88% | 13 | Nov 6, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $570 → $481 | $430.77 | +11.66% | 8 | Nov 4, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Overweight | $22 → $25 | $16.65 | +50.15% | 10 | Oct 23, 2024 | |
| RVNC Revance Therapeutics | Downgrades: Equal-Weight | $10 → $7 | $3.73 | +87.67% | 8 | Sep 13, 2024 | |
| EOLS Evolus | Maintains: Overweight | $20 → $16 | $13.51 | +18.43% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $8.57 | +16.69% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $11.66 | +54.37% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $50.42 | +19.00% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $200 | $121.58 | +64.50% | 9 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $230 | $176.81 | +30.08% | 14 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.29 | +203.95% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.37 | +410.95% | 7 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $15.57 | +79.83% | 1 | Sep 21, 2023 |
Phibro Animal Health
Nov 12, 2024
Maintains: Underweight
Price Target: $13 → $20
Current: $23.54
Upside: -15.04%
Pacira BioSciences
Nov 12, 2024
Maintains: Equal-Weight
Price Target: $25 → $17
Current: $17.81
Upside: -4.55%
Viatris
Nov 8, 2024
Maintains: Underweight
Price Target: $11 → $12
Current: $13.20
Upside: -9.09%
Elanco Animal Health
Nov 8, 2024
Maintains: Overweight
Price Target: $19 → $20
Current: $13.48
Upside: +48.37%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Overweight
Price Target: $125 → $150
Current: $122.70
Upside: +22.25%
Dr. Reddy's Laboratories
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.30
Upside: +18.88%
IDEXX Laboratories
Nov 4, 2024
Maintains: Overweight
Price Target: $570 → $481
Current: $430.77
Upside: +11.66%
Teva Pharmaceutical
Oct 23, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $16.65
Upside: +50.15%
Revance Therapeutics
Sep 13, 2024
Downgrades: Equal-Weight
Price Target: $10 → $7
Current: $3.73
Upside: +87.67%
Evolus
Sep 13, 2024
Maintains: Overweight
Price Target: $20 → $16
Current: $13.51
Upside: +18.43%
Aug 13, 2024
Maintains: Overweight
Price Target: $8 → $10
Current: $8.57
Upside: +16.69%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $11.66
Upside: +54.37%
May 10, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $50.42
Upside: +19.00%
May 3, 2024
Maintains: Overweight
Price Target: $230 → $200
Current: $121.58
Upside: +64.50%
Apr 23, 2024
Maintains: Overweight
Price Target: $260 → $230
Current: $176.81
Upside: +30.08%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.29
Upside: +203.95%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.37
Upside: +410.95%
Sep 21, 2023
Initiates: Overweight
Price Target: $28
Current: $15.57
Upside: +79.83%